MIR MedMira Inc

HALIFAX, Oct. 14, 2011 /CNW/ - MedMira Inc., ("MedMira") , a developer and marketer of rapid diagnostic technology and solutions, today announced that the Board of Directors granted a total of 3,290,000 options to purchase commons shares to its employees under the Stock Option Plan approved at the Company's AGM held on January 27, 2011. Of this total, 2,100,000 options were issued to Officers and Directors. The options are at an exercise prices of $0.10 per share and are exercisable for a period of three years. About MedMira MedMira is a leading developer and manufacturer of flow-through rapid diagnostics and technologies. The Company's tests provide hospitals, labs, clinics and individuals with reliable, rapid diagnosis of infectious diseases. MedMira diagnostics are sold under the Reveal®, MiraWell®, Multiplo™, and Miriad brands in global markets. MedMira's rapid HIV test is the only rapid HIV test in the world to achieve regulatory approvals in Canada, the United States, China and the European Union. MedMira's corporate offices and manufacturing facilities are located in Halifax, Nova Scotia, Canada. For more information visit MedMira's website at www.medmira.com. This news release contains forward-looking statements, including statements regarding development of sales opportunities, which involve risk and uncertainties and reflect the company's current expectation regarding future events.  Actual events could materially differ from those projected herein and depend on a number of factors including, but not limited to, changing market conditions, successful and timely completion of clinical studies, uncertainties related to the regulatory approval process, establishment of corporate alliances and other risks detailed from time to time in the company quarterly filings. The TSX Venture Exchange has not reviewed and does not accept responsibility for the adequacy or accuracy of this statement. MEDMIRA INC. CONTACT: MedMira Contact:Andrea YoungT. 902-450-1588E. ayoung@medmira.com

Copyright